Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Short-term Investments (2020 - 2025)

Ani Pharmaceuticals' Short-term Investments history spans 5 years, with the latest figure at $36000.0 for Q4 2025.

  • For Q4 2025, Short-term Investments rose 9.09% year-over-year to $36000.0; the TTM value through Dec 2025 reached $36000.0, up 9.09%, while the annual FY2025 figure was $36000.0, 9.09% up from the prior year.
  • Short-term Investments for Q4 2025 was $36000.0 at Ani Pharmaceuticals, roughly flat from $36000.0 in the prior quarter.
  • Across five years, Short-term Investments topped out at $5.0 million in Q4 2022 and bottomed at $33000.0 in Q4 2024.
  • The 4-year median for Short-term Investments is $36000.0 (2025), against an average of $2.3 million.
  • The largest annual shift saw Short-term Investments dropped 0.04% in 2021 before it increased 9.09% in 2025.
  • A 4-year view of Short-term Investments shows it stood at $5.0 million in 2021, then increased by 0.1% to $5.0 million in 2022, then tumbled by 99.34% to $33000.0 in 2024, then grew by 9.09% to $36000.0 in 2025.
  • Per Business Quant, the three most recent readings for ANIP's Short-term Investments are $36000.0 (Q4 2025), $36000.0 (Q3 2025), and $36000.0 (Q2 2025).